Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Nuwellis Inc (NUWE) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs Nuwellis Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.1 (market cap $44.49B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 20222.7× Nuwellis Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Nuwellis Inc for 26 Days on average.

JEPQNUWE
Market Cap
$44.49B$2.20M
Volume
5,681,789121,544
Sector
Income / Options OverlayHealth
52-Week High
$61.46$146.65
52-Week Low
$53.77$0.68
Typical Hold Time
66 Days26 Days
Enterprise Value
—-$1.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $61.07, down 0.33% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Financial media highlights JEPQ's 11% estimated yield and focus on Nasdaq technology exposure, though the strategy limits upside potential during strong bull markets.

JEPQ offers high monthly income through its covered-call approach on Nasdaq-100 stocks, making it attractive for income-focused investors. However, the strategy caps upside growth potential and distributions vary with market volatility. Key risks include concentrated tech exposure and dependence on options market conditions for income generation.

Nuwellis Inc

NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.

The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JEPQ
71% Buy29% Sell
Avg holding period · 66 Days
NUWE
2% Buy98% Sell
Avg holding period · 26 Days

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ →

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →